Cipla secured US FDA approval for its generic Advair Diskus®, a key therapy for asthma/COPD. The US market for this product is ~$908 million. Expected launch is Q2 FY27. This marks Cipla's first US-made dry powder inhaler approval, significantly boosting its respiratory capabilities and market presence.
Cipla's Board approved key leadership changes: Mr Achin Gupta appointed MD & Global CEO, Mr Dinesh Jain as Global CFO, Mr Rajendra Chopra as Company Secretary, and Ms Meera Vanjari as Chief General Counsel.
Cipla granted 5,530 stock options and 19,179 Employee Stock Appreciation Rights (ESARs) to employees. Issued at an exercise price of INR 2 per option/share, these schemes aim to incentivize staff.
Cipla achieved record revenue exceeding ₹28,000 Cr, with India business topping ₹12,500 Cr. Cash reserves are strong at ₹11,000 Cr. The company is advancing complex generics, biosimilars, and new product launches, including generic Ventolin. The Goa facility cleared inspection. A ₹13/share dividend was declared.
Cipla achieved record revenue exceeding ₹28,000 Cr, with India business crossing ₹12,500 Cr and cash reserves at ₹11,000 Cr. Global markets, including North America ($780M) and Africa ($483M), showed robust growth driven by new complex products like generic Ventolin. R&D spending (7% revenue) fuels future pipeline amidst US generics pricing...